Antengene doses first patient in Phase III CLINCH-3 trial
Antengene said the first patient has been dosed in its pivotal Phase III CLINCH-3 study evaluating ATG-022.
Antengene announced the first patient has been dosed in the pivotal Phase III CLINCH-3 study evaluating ATG-022.Material DetailsContext by AI AnalystThis is a late-stage advancement in Antengene’s clinical pipeline, moving ATG-022 into a pivotal setting. For this to become a larger catalyst, the tr…